DOCSLIB.ORG

RESEARCH BMJ: First Published As 10.1136/Bmj.C5222 on 20 October 2010

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
RESEARCH BMJ: First Published As 10.1136/Bmj.C5222 on 20 October 2010 RESEARCH BMJ: first published as 10.1136/bmj.c5222 on 20 October 2010. Downloaded from Tricyclic antidepressants and headaches: systematic review and meta-analysis Jeffrey L Jackson, director,4 William Shimeall, programme director,2 Laura Sessums, director,1 Kent J DeZee, programme director, general medicine fellowship,3 Dorothy Becher, research associate,1 Margretta Diemer, staff physician,1 Elizabeth Berbano, staff physician,1 Patrick G O’Malley, director, general internal medicine3 1General Medicine Division, Walter ABSTRACT between 8.4% and 18% worldwide.12 Tension-type Reed Army Medical Center, Objective To evaluate the efficacy and relative adverse headaches are even more common, occurring in 16- Washington, DC, USA 2 effects of tricyclic antidepressants in the treatment of 30% of people worldwide, with 3% having headaches Internal Medicine Residency, 2 National Naval Medical Center, migraine, tension-type, and mixed headaches. for more than 180 days a year. Migraine headaches Bethesda, MD, USA Design Meta-analysis. alone cost the United States $1bn (£0.64bn; €0.75bn) 3Uniformed Services University, Data sources Medline, Embase, the Cochrane Trials in medical costs and $13bn in lost productivity a year.3 Bethesda Registry, and PsycLIT. 4 Tricyclic antidepressants were first shown to be General Medicine Division, 4 Zablocki VA, 5000 W National Studies reviewed Randomised trials of adults receiving effective in preventing headaches in 1964 and have Avenue, Milwaukee, WI, 53295, tricyclics as only treatment for a minimum of four weeks. become a standard modality in headache USA Data extraction Frequency of headaches (number of prevention.5 Based on current standards for preventive Correspondence to: J L Jackson headache attacks for migraine and number of days with treatment in the United States, 43% of males and 34% [email protected] headache for tension-type headaches), intensity of of females who are candidates for such treatment are Cite this as: BMJ 2010;341:c5222 headache, and headache index. not receiving it.6 This may result from insufficient doi:10.1136/bmj.c5222 http://www.bmj.com/ Results 37 studies met the inclusion criteria. Tricyclics understanding of the magnitude of beneficial effects, significantly reduced the number of days with tension-type an overestimation of adverse effects, or the presump- headache and number of headache attacks from migraine tion that efficacy is only confined to migraine head- than placebo (average standardised mean difference aches. In a previous meta-analysis of antidepressants −1.29, 95% confidence interval −2.18 to −0.39 and −0.70, for headaches, we found that antidepressants were −0.93 to −0.48) but not compared with selective serotonin effective in preventing headaches, equally for ten- reuptake inhibitors (−0.80, −2.63 to 0.02 and −0.20, −0.60 sion-type headaches and migraine headaches.7 This to 0.19). The effect of tricyclics increased with longer meta-analysis was limited by the relatively small num- on 29 September 2021 by guest. Protected copyright. duration of treatment (β=−0.11, 95% confidence interval ber of available studies at the time. To expand on our −0.63 to −0.15; P<0.0005). Tricyclics were also more likely previous systematic review we assessed the efficacy to reduce the intensity of headaches by at least 50% than and tolerability of tricyclics in reducing the headache either placebo (tension-type: relative risk 1.41, 95% burden among adults with migraine or tension-type confidence interval 1.02 to 1.89; migraine: 1.80, 1.24 to headache. We also compared tricyclics with other 2.62) or selective serotonin reuptake inhibitors (1.73, 1.34 treatment modalities to assess whether the efficacy of to 2.22 and 1.72, 1.15 to 2.55). Tricyclics were more likely tricyclics varies by type of headache, dose, and dura- to cause adverse effects than placebo (1.53, 95% tion of treatment. confidence interval 1.11 to 2.12) and selective serotonin reuptake inhibitors (2.22, 1.52 to 3.32), including dry METHODS mouth (P<0.0005 for both), drowsiness (P<0.0005 for both), This report closely adheres to the PRISMA method for and weight gain (P<0.001 for both), but did not increase reporting on systematic reviews. We searched, without dropout rates (placebo: 1.22, 0.83 to 1.80, selective language restrictions, Medline (1966-March 2010) and serotonin reuptake inhibitors: 1.16, 0.81 to 2.97). Embase (1974-March 2010) using the search strategy Conclusions Tricyclic antidepressants are effective in (antidepressive agents, tricyclic OR antidepressive$ preventing migraine and tension-type headaches and are OR tricyclic$ OR amitriptyline OR amoxapine OR more effective than selective serotonin reuptake clomipramine OR desipramine OR dibenzepin OR inhibitors, although with greater adverse effects. The dothiepin OR doxepin OR imipramine OR lofepra- effectiveness of tricyclics seems to increase over time. mine OR nortriptyline OR opipramol OR protripty- line OR trimipramine) AND (headache or headache INTRODUCTION disorders or headache$ OR migrain$ OR tension$ Headaches are common and cause distress and disabil- OR cephalgi$ OR cephalalgi$). We also searched ity. The prevalence of migraine headaches ranges CRISP and FEDRIP databases for unpublished BMJ | ONLINE FIRST | bmj.com page 1 of 13 RESEARCH literature. In addition we searched the Cochrane Pain, headache. Studies reporting less than 50% improve- BMJ: first published as 10.1136/bmj.c5222 on 20 October 2010. Downloaded from Palliative and Supportive Care Trials Register; the ment were not abstracted. We assessed article quality Cochrane Central Register of Controlled Trials; Psy- independently and in duplicate (DB, JLJ) using the risk cLIT (1974-2002); and PsycINFO (1974-March 2010), of bias assessment tool developed by the Cochrane and carried out a review of the bibliographies of all collaboration,12 with good inter-rater agreement articles retrieved. The last search date was 25 March (Cochrane: κ=0.83). Disagreements were resolved by 2010. The search was supplemented by searches car- consensus. ried out by medical librarians at our institution as well as the Cochrane clinical research group. Statistical analysis We included published, randomised clinical trials Because reported measures for headache varied, a that evaluated the efficacy of tricyclic antidepressants priori we preferentially abstracted and pooled data in reducing the frequency or severity of migraine or on headache measures in this order: frequency of head- tension-type headaches. Treatment groups were ache, intensity of headache, and headache index, per required to receive a tricyclic regularly at any dosing the recommendations of the reviewers of our schedule as a single intervention for at least four weeks. Cochrane protocol. For frequency we used the number Tricyclics could not be combined with other drugs of headache attacks for migraines and number of days with possible prophylactic benefit or effect augmenta- with headache for tension-type headaches. Intensity tion. Comparison groups could receive placebo or a was abstracted in the scale used by each study; some specified alternative drug or non-drug treatment. studies used visual analogue scales, others used other Additional inclusion criteria required studies to continuous measures of intensity. Many studies used a include only adults (>18 years) with migraine or ten- “headache index” to sum aspects of the burden of sion-type headache (frequent episodic or chronic) that headache, usually derived by multiplying the fre- could reasonably be defined on the basis of diagnostic quency of the headache by intensity. In addition we criteria described in 1988 by the International Head- pooled analgesic use. Because of differences in mea- ache Society8 or earlier.910 We excluded secondary surement of headache burden between studies, we headaches, such as those related to drug overuse, con- pooled standardised differences between studies, a cussion, or lumbar puncture. Because the classification measure also known as an effect size. By convention, of headache has changed over time, two authors inde- effect sizes greater than 0.8 are considered as large, pendently reviewed each included article’s definition those between 0.6 and 0.8 as moderate, and those of headache and, where possible, classified it according between 0.2 and 0.6 as small.13 http://www.bmj.com/ to the most recent criteria of the International Head- For studies with more than one arm, we pooled the ache Society.8 data for all arms into one group; if this was not possible we reduced the sample size for each arm by 50% to Study selection and data abstraction prevent overweighting studies. We pooled data using We selected articles for inclusion in two stages. In the the DerSimonian and Laird random effects model.14 first stage two researchers (PGO’M, KJD) indepen- Regardless of headache type, we pooled all studies dently reviewed titles and abstracts to select full text with stratified analysis to provide estimates for each articles for retrieval. A priori we decided to include subgroup, and used metaregression to test for differ- on 29 September 2021 by guest. Protected copyright. all articles recommended by either reviewer for full ences between these groups. Heterogeneity was text retrieval. Agreement was only modest during this assessed visually using Galbraith plots15 and the I2 stage (κ=0.66). During the second stage two other statistic.16 For continuous data (such as headache fre- researchers (LS, MD) independently applied inclusion quency and
Load more

Recommended publications
  • Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid
    Clinical Policy: Anti-Migraine Agents Reference Number: OH.PHAR.PPA.34 Effective Date: 01.01.21 Last Review Date: 11.20 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory and legal information. Description • When using a preferred agent where applicable, the number of tablets/doses allowed per month will be restricted based on the manufacturer’s package insert and/or Buckeye Health plans quantity limits. CNS AGENTS: ANTI-MIGRAINE AGENTS – ACUTE MIGRANE TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” “PREFERRED” NARATRIPTAN (GENERIC OF AMERGE®) NURTEC™ ODT (rimegepant) ALMOTRIPTAN (generic of Axert®) RIZATRIPTAN TABLETS (GENERIC OF CAFERGOT® (ergotamine w/caffeine) MAXALT®) ELETRIPTAN (generic of Relpax®) RIZATRIPTAN ODT (GENERIC OF ERGOMAR® (ergotamine) MAXALT-MLT®) FROVA® (frovatriptan) SUMATRIPTAN TABLETS, NASAL SPRAY, MIGERGOT® (ergotamine w/caffeine) INJECTION (GENERIC OF MIGRANAL® (dihydroergotamine) IMITREX®) ONZETRA™ XSAIL™ (sumatriptan) REYVOW™ (lasmiditan) SUMAVEL DOSEPRO® (sumatriptan) TOSYMRA® (sumatriptan) TREXIMET® (sumatriptan/naproxen) UBRELVY™ (ubrogepant)* ZOLMITRIPTAN (generic of Zomig®) ZOLMITRIPTAN ODT (generic of Zomig ZMT®) ZOMIG® NASAL SPRAY (zolmitriptan) CNS AGENTS: ANTI-MIGRAINE AGENTS – CLUSTER HEADACHE TREATMENT NO PA REQUIRED “PREFERRED” PA REQUIRED “NON-PREFERRED” VERAPAMIL (Generic of Calan®) EMGALITY™ (galcanezumab) VERAPAMIL SR/ER (Generic of Calan SR®, Isoptin SR®, Verelan®) CNS AGENTS: ANTI-MIGRAINE AGENTS – PROPHYLAXIS TREATMENT NO PA REQUIRED “PREFERRED” STEP THERAPY REQUIRED PA REQUIRED “NON-PREFERRED” (Trials of at least 3 controller “PREFERRED” medications) Cardiovascular Agents: Beta-blockers AIMOVIG™ (erenumab-aooe) † EMGALITY™ (galcanezumab) CNS Agents: Anticonvulsants AJOVY™ (fremanezumab-vfrm) * CNS Agents: Serotonin-norepinephrine reuptake inhibitors CNS Agents: Tricyclic antidepressants †Initial Dose is limited to 70mg once monthly; may request dose increase if 70mg fails to provide adequate relief over two consecutive months.
    [Show full text]
  • Biased Ligands Differentially Shape the Conformation of The
    International Journal of Molecular Sciences Article Biased Ligands Differentially Shape the Conformation of the Extracellular Loop Region in 5-HT2B Receptors Katrin Denzinger, Trung Ngoc Nguyen, Theresa Noonan, Gerhard Wolber and Marcel Bermudez * Institute of Pharmacy, Freie Universität Berlin, Königin-Luise-Strasse 2-4, 14195 Berlin, Germany; [email protected] (K.D.); [email protected] (T.N.N.); [email protected] (T.N.); [email protected] (G.W.) * Correspondence: [email protected] Received: 22 November 2020; Accepted: 18 December 2020; Published: 20 December 2020 Abstract: G protein-coupled receptors are linked to various intracellular transducers, each pathway associated with different physiological effects. Biased ligands, capable of activating one pathway over another, are gaining attention for their therapeutic potential, as they could selectively activate beneficial pathways whilst avoiding those responsible for adverse effects. We performed molecular dynamics simulations with known β-arrestin-biased ligands like lysergic acid diethylamide and ergotamine in complex with the 5-HT2B receptor and discovered that the extent of ligand bias is directly connected with the degree of closure of the extracellular loop region. Given a loose allosteric coupling of extracellular and intracellular receptor regions, we delineate a concept for biased signaling at serotonin receptors, by which conformational interference with binding pocket closure restricts the signaling repertoire of the receptor. Molecular docking studies of biased ligands gathered from the BiasDB demonstrate that larger ligands only show plausible docking poses in the ergotamine-bound structure, highlighting the conformational constraints associated with bias. This emphasizes the importance of selecting the appropriate receptor conformation on which to base virtual screening workflows in structure-based drug design of biased ligands.
    [Show full text]
  • Wednesday, July 10, 2019 4:00Pm
    Wednesday, July 10, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – July 10, 2019 DATE: July 3, 2019 NOTE: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the July meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/SoonerPsych Program Update – Appendix B Action Item – Vote to Prior Authorize Jornay PM™ [Methylphenidate Extended-Release (ER) Capsule], Evekeo ODT™ [Amphetamine Orally Disintegrating Tablet (ODT)], Adhansia XR™ (Methylphenidate ER Capsule), and Sunosi™ (Solriamfetol Tablet) – Appendix C Action Item – Vote to Prior Authorize Balversa™ (Erdafitinib) – Appendix D Action Item – Vote to Prior Authorize Annovera™ (Segesterone Acetate/Ethinyl Estradiol Vaginal System), Bijuva™ (Estradiol/Progesterone Capsule), Cequa™ (Cyclosporine 0.09% Ophthalmic Solution), Corlanor® (Ivabradine Oral Solution), Crotan™ (Crotamiton 10% Lotion), Gloperba® (Colchicine Oral Solution), Glycate® (Glycopyrrolate Tablet), Khapzory™ (Levoleucovorin Injection), Qmiiz™ ODT [Meloxicam Orally Disintegrating Tablet (ODT)], Seconal Sodium™ (Secobarbital
    [Show full text]
  • Ergotamine | Memorial Sloan Kettering Cancer Center
    PATIENT & CAREGIVER EDUCATION Ergotamine This information from Lexicomp® explains what you need to know about this medication, including what it’s used for, how to take it, its side effects, and when to call your healthcare provider. Brand Names: US Ergomar Warning Poor blood flow to the hands, feet, or brain has happened when this drug was taken with certain other drugs like clarithromycin, erythromycin, indinavir, itraconazole, ketoconazole, nelfinavir, ritonavir, and troleandomycin. This may be very bad or even deadly. Do not take this drug if you are taking any of these drugs. There are many drugs that can do this. Check to make sure that it is safe for you to take this drug with all of your drugs. What is this drug used for? It is used to treat migraine headaches. What do I need to tell my doctor BEFORE I take this drug? If you are allergic to this drug; any part of this drug; or any other drugs, foods, or substances. Tell your doctor about the allergy and what signs you had. If you have any of these health problems: Blood vessel disease, heart disease, high blood pressure, kidney disease, liver disease, or a very bad infection. If you have taken almotriptan, eletriptan, frovatriptan, naratriptan, rizatriptan, Ergotamine 1/6 sumatriptan, or zolmitriptan in the last 24 hours. If you are pregnant or may be pregnant. Do not take this drug if you are pregnant. If you are breast-feeding or plan to breast-feed. This is not a list of all drugs or health problems that interact with this drug.
    [Show full text]
  • PRESCRIBED DRUGS and NEUROLOGICAL COMPLICATIONS K a Grosset, D G Grosset Iii2
    J Neurol Neurosurg Psychiatry: first published as 10.1136/jnnp.2004.045757 on 16 August 2004. Downloaded from PRESCRIBED DRUGS AND NEUROLOGICAL COMPLICATIONS K A Grosset, D G Grosset iii2 J Neurol Neurosurg Psychiatry 2004;75(Suppl III):iii2–iii8. doi: 10.1136/jnnp.2004.045757 treatment history is a fundamental part of the healthcare consultation. Current drugs (prescribed, over the counter, herbal remedies, drugs of misuse) and how they are taken A(frequency, timing, missed and extra doses), drugs tried previously and reason for discontinuation, treatment response, adverse effects, allergies, and intolerances should be taken into account. Recent immunisations may also be of importance. This article examines the particular relevance of medication in patients presenting with neurological symptoms. Drugs and their interactions may contribute in part or fully to the neurological syndrome, and treatment response may assist diagnostically or in future management plans. Knowledge of medicine taking behaviour may clarify clinical presentations such as analgesic overuse causing chronic daily headache, or severe dyskinesia resulting from obsessive use of dopamine replacement treatment. In most cases, iatrogenic symptoms are best managed by withdrawal of the offending drug. Indirect mechanisms whereby drugs could cause neurological problems are beyond the scope of the current article—for example, drugs which raise blood pressure or which worsen glycaemic control and consequently increase the risk of cerebrovascular disease, or immunosupressants
    [Show full text]
  • Still the Leading Antidepressant After 40 Years of Randomised Controlle
    BRITISH JOURNAL OF PSYCHIATRY "2001), 178, 129^144 REVIEW ARTICLE Amitriptyline vv.therest:stilltheleading METHOD Inclusion criteria antidepressant after 40 years of randomised All RCTs comparing amitriptyline with any y other tricyclic,heterocyclic or SSRI were in- controlled trials cluded. Crossover studies were excluded. Studies adopting any criteria to define CORRADO BARBUI and MATTHEW HOTOPF patients suffering from depression were included; a concurrent diagnosis of another psychiatric disorder was not considered an exclusion criterion. Trials in patients with depression with a concomitant medical ill- Background Tricyclic antidepressants Amitriptyline is one of the first `reference' ness were not included in this review. have similar efficacy and slightly lower tricyclic antidepressants TCAs). Over the past 40 years a number of newer tricyclics, tolerability than selective serotonin Search strategy heterocyclics and selective serotonin re- Relevant studies were located by searching reuptakeinhibitorsreuptake inhibitors SSRIs).However, uptake inhibitors SSRIs) have been intro- the Cochrane Collaboration Depression, there are no systematic reviews assessing duced Garattini et aletal,1998). Despite Anxiety and Neurosis Controlled Trials several large systematic reviews comparing amitriptyline, the reference tricyclic drug, Register CCDANCTR). This specialised tricyclics and SSRIs there is no clear agree- vv. other tricyclics and SSRIs directly. register is regularly updated by electronic ment over first-line treatment of depression Medline,Embase,PsycINFO,LILACS, SongSong et aletal,1993; Anderson & Tomenson, Aims ToreviewTo review the tolerability and Psyndex,CINAHL,SIGLE) and non-electro- 1995; Montgomery & Kasper,1995; efficacy of amitriptyline inthe nicnicliterature searches. The register was HotopfHotopf et aletal,1996; Canadian Coordinating management of depression. searched using the following terms: Office for Health Technology Assessment, AMITRIPTYLIN**AMITRIPTYLIN oror AMITRILAMITRIL oror ELA-ELA- 19971997aa).
    [Show full text]
  • Use of Amitriptyline for the Treatment of Chronic Tension-Type Headache
    Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. Amitriptyline and chronic tension-type headache Publication Types: Review Use of amitriptyline for the treatment of chronic tension-type headache. Review of the literature Eulalia Torrente Castells 1, Eduardo Vázquez Delgado 2, Cosme Gay Escoda 3 (1) Odontóloga. Residente del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona (2) Odontólogo. Profesor Asociado de Cirugía Bucal. Profesor responsable de la Unidad de Patología de la ATM y Dolor Bucofacial del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Especialista de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona (3) Médico-Estomatólogo y Cirujano Maxilofacial. Catedrático de Patología Quirúrgica Bucal y Maxilofacial. Director del Máster de Cirugía Bucal e Implantología Bucofacial. Facultad de Odontología de la Universidad de Barcelona. Co-director de la Unidad de Patología de la ATM y Dolor Bucofacial del Centro Médico Teknon. Barcelona Correspondence: Prof. Cosme Gay Escoda Centro Médico Teknon C/Vilana nº 12 08022 Barcelona E-mail: [email protected] Torrente-Castells E, Vázquez-Delgado E, Gay-Escoda C. Use of amitrip- Received: 28/09/2007 tyline for the treatment of chronic tension-type headache. Review of the Accepted: 11/07/2008 literature. Med Oral Patol Oral Cir Bucal. 2008 Sep1;13(9):E567-72. © Medicina Oral S. L. C.I.F. B 96689336 - ISSN 1698-6946 Indexed in: http://www.medicinaoral.com/medoralfree01/v13i9/medoralv13i9p567.pdf -Index Medicus / MEDLINE / PubMed -EMBASE, Excerpta Medica -SCOPUS -Indice Médico Español -IBECS Abstract Amitriptyline is a tricyclic antidepressant, considered the treatment of choice for different types of chronic pain, including chronic myofascial pain.
    [Show full text]
  • Package Leaflet: Information for the Patient Dostinex® 0.5 Mg Tablets
    Package leaflet: Information for the patient Dostinex® 0.5 mg Tablets cabergoline Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet 1. What Dostinex is and what it is used for 2. What you need to know before you take Dostinex 3. How to take Dostinex 4. Possible side effects 5 How to store Dostinex 6. Contents of the pack and other information 1. What Dostinex is and what it is used for - Dostinex contains the active ingredient cabergoline. This medicine belongs to a class of medicines called ‘dopamine agonists’. Dopamine is produced naturally in the body and helps to transmit messages to the brain. - Dostinex is used to stop breast milk production (lactation) soon after childbirth, stillbirth, abortion or miscarriage. It can also be used if you do not want to continue to breast-feed your baby once you have started. - Dostinex can also be used to treat other conditions caused by hormonal disturbance which can result in high levels of prolactin being produced. This includes lack of periods, infrequent and very light menstruation, periods in which ovulation does not occur and secretion of milk from your breast without breast-feeding.
    [Show full text]
  • Pharmacokinetic and Pharmacodynamic Interactions Between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy
    University of Kentucky UKnowledge Psychiatry Faculty Publications Psychiatry 11-2014 Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Domenico Italiano University of Messina, Italy Edoardo Spina University of Messina, Italy Jose de Leon University of Kentucky, [email protected] Right click to open a feedback form in a new tab to let us know how this document benefits oy u. Follow this and additional works at: https://uknowledge.uky.edu/psychiatry_facpub Part of the Psychiatry and Psychology Commons Repository Citation Italiano, Domenico; Spina, Edoardo; and de Leon, Jose, "Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants" (2014). Psychiatry Faculty Publications. 40. https://uknowledge.uky.edu/psychiatry_facpub/40 This Article is brought to you for free and open access by the Psychiatry at UKnowledge. It has been accepted for inclusion in Psychiatry Faculty Publications by an authorized administrator of UKnowledge. For more information, please contact [email protected]. Pharmacokinetic and Pharmacodynamic Interactions between Antiepileptics and Antidepressants Notes/Citation Information Published in Expert Opinion on Drug Metabolism & Toxicology, v. 10, Issue 11, p. 1457-1489. © 2014 Taylor & Francis Group This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov. 2014, available online: http://www.tandfonline.com/10.1517/ 17425255.2014.956081 Digital Object Identifier (DOI) http://dx.doi.org/10.1517/17425255.2014.956081 This article is available at UKnowledge: https://uknowledge.uky.edu/psychiatry_facpub/40 1 This is an Accepted Manuscript of an article published by Taylor & Francis Group in Expert Opinion on Drug Metabolism & Toxicology in Nov.
    [Show full text]
  • Albert Hofmann's Pioneering Work on Ergot Alkaloids and Its Impact On
    BIRTHDAY 83 CHIMIA 2006, 60, No. 1/2 Chimia 60 (2006) 83–87 © Schweizerische Chemische Gesellschaft ISSN 0009–4293 Albert Hofmann’s Pioneering Work on Ergot Alkaloids and Its Impact on the Search of Novel Drugs at Sandoz, a Predecessor Company of Novartis Dedicated to Dr. Albert Hofmann on the occasion of his 100th birthday Rudolf K.A. Giger* and Günter Engela Abstract: The scientific research on ergot alkaloids is fundamentally related to the work of Dr. Albert Hofmann, who was able to produce, from 1935 onwards, a number of novel and valuable drugs, some of which are still in use today. The complex chemical structures of ergot peptide alkaloids and their pluripotent pharmacological activity were a great challenge for Dr. Hofmann and his associates who sought to unravel the secrets of the ergot peptide alkaloids; a source of inspiration for the design of novel, selective and valuable medicines. Keywords: Aminocyclole · Bromocriptine Parlodel® · Dihydroergotamine Dihydergot® · Dihydro ergot peptide alkaloids · Ergobasin/ergometrin · Ergocornine · Ergocristine · α- and β-Ergocryptine · Ergolene · Ergoline · Ergoloid mesylate Hydergine® · Ergotamine Gynergen® · Ergotoxine · Lisuride · Lysergic acid diethylamide LSD · Methylergometrine Methergine® · Methysergide Deseril® · Paspalic acid · Pindolol Visken® · Psilocybin · Serotonin · Tegaserod Zelmac®/Zelnorm® · Tropisetron Navoban® Fig. 1. Albert Hofmann in 1943, 1979 and 2001 (Photos in 2001 taken by J. Zadrobilek and P. Schmetz) Dr. Albert Hofmann (Fig. 1), born on From the ‘Ergot Poison’ to *Correspondence: Dr. R.K.A. Giger January 11, 1906, started his extremely Ergotamine Novartis Pharma AG NIBR Global Discovery Chemistry successful career in 1929 at Sandoz Phar- Lead Synthesis & Chemogenetics ma in the chemical department directed The scientific research on ergot alka- WSJ-507.5.51 by Prof.
    [Show full text]
  • New Zealand Data Sheet
    New Zealand Data Sheet 1 CAFERGOT (ERGOTAMINE TARTRATE 1 MG AND CAFFEINE 100 MG TABLET) CAFERGOT ergotamine tartrate 1 mg and caffeine 100 mg tablet 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Ergotamine tartrate 1 mg and Caffeine 100 mg For the full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Cafergot tablets are round, flat with bevelled edge, 9 mm diameter, speckled yellow/white, inscribed with a breakline and XL on one side and plain on the other side. 4 CLINICAL PARTICULARS 4.1 Therapeutic indications Treatment of acute attacks of migraine with or without aura in adults. 4.2 Dose and method of administration Cafergot should be given at the first signs of a migraine attack. Dose Adults First attack: The first time Cafergot is taken, an initial dose of 2 Cafergot tablets orally, is recommended. If relief is not obtained within half an hour, a further tablet should be administered; this may be repeated at half-hourly intervals, but the maximum daily dose of 6 tablets should not be exceeded. Subsequent attacks: If the pain persists, take 1 tablet every half an hour up to the maximum daily dose of 6 tablets. The maximum weekly dose is 10 tablets. Children under 18 years Not recommended. Maximum dose per attack or per day Adults: 6 mg ergotamine tartrate = 6 tablets. Maximum weekly dose Adults: 10 mg ergotamine tartrate = 10 tablets. Special populations Renal impairment Cafergot is contraindicated in patients with severe renal impairment (see Contraindications). Hepatic impairment Cafergot is contraindicated in patients with severe hepatic impairment (see Contraindications).
    [Show full text]
  • Wednesday, June 12, 2019 4:00Pm
    Wednesday, June 12, 2019 4:00pm Oklahoma Health Care Authority 4345 N. Lincoln Blvd. Oklahoma City, OK 73105 The University of Oklahoma Health Sciences Center COLLEGE OF PHARMACY PHARMACY MANAGEMENT CONSULTANTS MEMORANDUM TO: Drug Utilization Review (DUR) Board Members FROM: Melissa Abbott, Pharm.D. SUBJECT: Packet Contents for DUR Board Meeting – June 12, 2019 DATE: June 5, 2019 Note: The DUR Board will meet at 4:00pm. The meeting will be held at 4345 N. Lincoln Blvd. Enclosed are the following items related to the June meeting. Material is arranged in order of the agenda. Call to Order Public Comment Forum Action Item – Approval of DUR Board Meeting Minutes – Appendix A Update on Medication Coverage Authorization Unit/Use of Angiotensin Converting Enzyme Inhibitor (ACEI)/ Angiotensin Receptor Blocker (ARB) Therapy in Patients with Diabetes and Hypertension (HTN) Mailing Update – Appendix B Action Item – Vote to Prior Authorize Aldurazyme® (Laronidase) and Naglazyme® (Galsulfase) – Appendix C Action Item – Vote to Prior Authorize Plenvu® [Polyethylene Glycol (PEG)-3350/Sodium Ascorbate/Sodium Sulfate/Ascorbic Acid/Sodium Chloride/Potassium Chloride] – Appendix D Action Item – Vote to Prior Authorize Consensi® (Amlodipine/Celecoxib) and Kapspargo™ Sprinkle [Metoprolol Succinate Extended-Release (ER)] – Appendix E Action Item – Vote to Update the Prior Authorization Criteria For H.P. Acthar® Gel (Repository Corticotropin Injection) – Appendix F Action Item – Vote to Prior Authorize Fulphila® (Pegfilgrastim-jmdb), Nivestym™ (Filgrastim-aafi),
    [Show full text]